Featured Research

from universities, journals, and other organizations

WHO Panel Recommends Single, Simple Test For New TB Vaccine Trials

Date:
June 30, 2008
Source:
Public Library of Science
Summary:
The World Health Organization Initiative for Vaccine Research recently convened a panel of TB vaccine trial experts to examine the best way of testing immunity in blood taken from people vaccinated with a new TB vaccine. Phase three trials focus on testing whether the vaccines will work to protect people against TB.

The World Health Organization Initiative for Vaccine Research recently convened a panel of TB vaccine trial experts to examine the best way of testing immunity in blood taken from people vaccinated with a new TB vaccine.

"The panel recognised that many new and diverse tuberculosis vaccines are currently under development," says the lead author Professor Hanekom, of the South African TB Vaccine Initiative. "The ability to compare results of how the immune systems of people who received these vaccines have responded would be an important asset for TB vaccine research globally." Previously, it has been difficult to compare results because of differences in laboratory approaches, logistics and diverse populations being tested.

The panel evaluated advantages and disadvantages of many types of immune tests, and made specific recommendations for human trials of new vaccines, which included introducing a single and simple test that is used in all vaccine trials.

"The panel recommended the use of a test that had performed excellently, that could yield informative results, and that could be implemented in even the most remote of field sites," says Professor Hanekom. "It is anticipated that this single and simple test will speed up decision-making on which of the new TB vaccines currently being tested globally will proceed to phase three trials."

Phase three trials focus on testing whether the vaccines will work to protect people against TB. The single and simple test recommended by the panel would allow comparison of results on the human immune response to all new TB vaccines currently being tested by the many research initiatives globally. If implemented, this could shorten the process to find an effective vaccine against TB.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hanekom et al. Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations. PLoS Medicine, 2008; 5 (7): e145 DOI: 10.1371/journal.pmed.0050145

Cite This Page:

Public Library of Science. "WHO Panel Recommends Single, Simple Test For New TB Vaccine Trials." ScienceDaily. ScienceDaily, 30 June 2008. <www.sciencedaily.com/releases/2008/06/080630201004.htm>.
Public Library of Science. (2008, June 30). WHO Panel Recommends Single, Simple Test For New TB Vaccine Trials. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/06/080630201004.htm
Public Library of Science. "WHO Panel Recommends Single, Simple Test For New TB Vaccine Trials." ScienceDaily. www.sciencedaily.com/releases/2008/06/080630201004.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins